ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AMLX vs TNGX // OPERATING MARGIN

Amylyx Pharmaceuticals Inc. (NASDAQ) VS. Tango Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: AMLX 2 — TNGX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. TNGX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AMLX TNGX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.90% -6.10 TNGX /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -3.43% -3.68% +0.25 AMLX /fcf-yield <GO>
Operating Margin ACTIVE — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 48.30% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 26.00 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 TNGX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.9 46.9 +5.00 AMLX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.87 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 28.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $3.62B $3.83B -$210.1M TNGX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AMLX REV TNGX REV AMLX GROSS % TNGX GROSS % AMLX FCF TNGX FCF
FY 2025 $0 $62.4M — — -$123.5M -$139.9M
FY 2024 $87.4M $42.1M 93.2% — -$167.8M -$132.3M
FY 2023 $380.8M $36.5M — — $11.9M -$119.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMLX // BETA —
TNGX // BETA 0.87